Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Nivolumab in combination with stereotactic body radiotherapy does not provide evidence of an added benefit in patients with pretreated metastatic renal cell carcinoma; however, it should be evaluated in patients with oligometastic or oligoprogressive disease. This approach was safe and showed a faster time to treatment response, median duration of response, and good response of the irradiated lesions.